PDX Model Cohort
Diffuse Large B Cell & Non-Hodgkin's Lymphoma PDX Models (NHL) & (DLBCL)
An advanced cohort of well-characterized Diffuse Large B Cell & Non-Hodgkin's Lymphoma PDX Models directly established from patient tumors available for drug development research
Summary
Champions Oncology offers 15* well-characterized DLBCL and Non-Hodgkin's Lymphoma PDX models to support oncology drug development. These models represent key subtypes such as ABC and GCB and are annotated with patient clinical data, treatment history, and in vivo responses to various therapies. All models have undergone RNA-Seq analysis, and Champions continues to expand the PDX bank with models derived from patients who have progressed on current standard treatments, including CHOP regimens. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading NHL & DLBCL Lymphoma PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to one of the largest bank of NHL & DLBCL Lymphoma PDX Models models with clinically relevant molecular and pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with advanced therapies like (cyclophosphamide, doxorubicinHCl, vincristine [Oncovin], prednisone and more.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes